The OS difference in the hormone receptor-negative subgroup with a non-significant trend in RFS may be confounded by deaths unrelated to BC, or differences in the type of relapse (e.g. distant versus locoregional), which may affect subsequent survival status (Fig. 1). This evidence concerns the gene NR4A1 and breast cancer.